Phase I and pilot study of subcutaneous homoharringtonine [omacetaxine mepesuccinate] in chronic myelogenous leukemia (CML).
Phase of Trial: Phase I
Latest Information Update: 22 Jan 2013
At a glance
- Drugs Omacetaxine mepesuccinate (Primary)
- Indications Chronic myeloid leukaemia
- Focus Adverse reactions; Pharmacokinetics; Therapeutic Use
- 13 Dec 2008 Trial phase changed from I to II as reported by ClinicalTrials.gov.
- 25 Sep 2005 New trial record.